【摘要】 目的明确易瑞沙二线治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法50例经组织学或细胞学检查确诊的ⅢB或Ⅳ期NSCLC患者,随机分为两组,分别接受易瑞沙250mg/d,口服,或多西紫杉醇75mg/m2,第1天,静脉滴注,顺铂75mg/m2,静脉滴注,第1天,每21天为1个周期。结果两组均无CR,多西紫杉醇组(A组)和易瑞沙组(B组)总有效率分别为24%和32%,1年生存率分别为32%和40%,两组差异无统计学意义(P=0.529,P=0.556)。易瑞沙治疗组副反应以轻度皮疹和腹泻为主,多西紫杉醇组主要为消化道反应、骨髓抑制、脱发等,耐受性方面,易瑞沙具有明显优势。结论易瑞沙和多西紫杉醇联合顺铂3周方案二线治疗NSCLC相比,疗效相似,但毒性明显下降,耐受性好。更多还原

【Abstract】 Objective To evaluate the antitumor efficiency and toxicity of Iressa in advanced non-small-cell lung cancer(NSCLC).Methods 50 patients with stage ⅢB or Ⅳ NSCLC(proved by histology or cytology)were randomly divided into two groups.Patients received oral Iressa 250 mg/day or docetaxel 75 mg/m2,ivgtt day1,cisplatin 75 mg/m2,ivgtt day 1,repeated every 21 days.Results There was no CR in both groups.The overall response rate was 24% and 32% in docetaxel group(A)and Iressa group(B).The one-year survival rate was 32% and 40% respectively.There were no significant difference for twogroups(P=0.529>,P=0.556).The most common adverse effects of Iressa were skin reactions and diarrhea which were generally mild.The main side effects of docetaxel group were gastrointestinal reactions、myelosuppression、alopecia et.Iressa had obvious advantages in tolerance.Conclusion In comparison with the 3-weeks’docetaxel/cisplatin chemotherapy,Iressa had similar response rate with lower toxicitiesand better tolerated.更多还原